| Pharmaceutical Information |
| Drug Name |
Canagliflozin |
| Drug ID |
BADD_D00344 |
| Description |
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label].
It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus [L5897], [FDA label].
Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897]. Cardiovascular disease is the most common cause of death in these patients [A177083]. |
| Indications and Usage |
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus [FDA label].
Another indication for canagliflozin is the prevention of major cardiovascular events (myocardial infarction, stroke, or death due to a cardiovascular cause) in patients with type 2 diabetes, as well as hospitalization for heart failure in patients with type 2 diabetes[L5897,[L8917].
In addition to the above, canagliflozin can be used to lower the risk of end-stage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus, diabetic nephropathy, and albuminuria.[L8917]
It is important to note that this drug is **not** indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis [FDA label]. |
| Marketing Status |
approved |
| ATC Code |
A10BK02 |
| DrugBank ID |
DB08907
|
| KEGG ID |
D09592
|
| MeSH ID |
D000068896
|
| PubChem ID |
24812758
|
| TTD Drug ID |
D08DFX
|
| NDC Product Code |
55111-978; 50923-1216; 50090-4364; 12578-615; 59651-065; 17314-575; 50090-5029; 50090-5033; 12578-611; 14445-017; 42385-735; 70966-0001; 17314-577; 50090-5034; 55154-1425; 50458-140; 50458-141; 55154-1426 |
| UNII |
0SAC974Z85
|
| Synonyms |
Canagliflozin | Invokana | Canagliflozin Hemihydrate | Canagliflozin, Anhydrous | 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973 |
|
| Chemical Information |
| Molecular Formula |
C24H25FO5S |
| CAS Registry Number |
842133-18-0 |
| SMILES |
CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
